)
Andrew Dunn
Senior Biopharma Correspondent
Endpoints News
Andrew Dunn is a senior biopharma correspondent at Endpoints News, covering the money and science shaping the future of biotech and pharma. His beat focuses on AI in biotech, where he breaks news on startup launches, major financings, and the strategic moves defining the industry. He also reports deep enterprise stories from inside the labs and boardrooms of leading biopharma companies. A frequent moderator at industry conferences, Andrew launched Endpoints' AI Day in 2024.
Sessions
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}